(NP (-LRB- -LCB-) (NP-COOD (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (JJ leucocytic) (NN estrogen) (NN receptor)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ menopausal) (NN type) (CD II) (NNS diabetes)))))))))) (CC and) (NP (PRP$ its) (NN significance))) (-RRB- -RCB-))
(S (NP-SBJ-43 (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NP (NN estrogen) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ human) (JJ peripheral) (NNS leucocytes)) (PP (IN in) (NP (NP (CD 12) (NNS women)) (PP (IN with) (NP (JJ menopausal) (NN type) (CD II) (NNS diabetes)))))))))) (VP (VBD was) (VP (VBN measured) (NP (-NONE- *-43)) (PP (IN with) (NP (JJ radio-ligand) (NN binding) (NN method))))) (. .))
(S (NP-SBJ-44 (DT The) (NNS results)) (VP (VBD were) (VP (VBN compared) (NP (-NONE- *-44)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP-COOD (NP (NP (CD 12) (JJ menopausal) (NNS women)) (PP (IN without) (NP (NNS diabetes)))) (CC and) (NP (NP (CD 12) (JJ normal) (NNS women)) (PP (IN of) (NP (JJ childbearing) (NN age)))))))))) (. .))
(S (NP-SBJ (PRP It)) (VP (VBD was) (VP (VBN found) (SBAR (IN that) (S (NP-SBJ-45 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN ER)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (NP (-NONE- *-45)))))))) (. .))
(S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN decrease)) (PP (IN of) (NP (NP (NN ER) (NN level)) (PP (IN in) (NP (NNS leukocytes)))))) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ related) (PP (TO to) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN type) (CD II) (NNS diabetes))) (PP (IN in) (NP (JJ menopausal) (NN period))))))))))) (. .))
